Chlorothiazide-reserpine

   
Google
 
Web NewDrugInformation.com

Chlorothiazide-reserpine


Drug - Chlorothiazide-reserpine
The trade name of the product as shown on the labeling.

Dosage - TABLET; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Chlorothiazide; Reserpine
Multiple ingredients are in alphabetical order.

Strength - 500MG;0.125MG
The potency of the active ingredient(s), Chlorothiazide; Reserpine. May repeat for multiple part products.

Applicant - MYLAN
The firm name holding legal responsibility for Chlorothiazide-reserpine. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 087745
The FDA assigned number to Chlorothiazide-reserpine. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Chlorothiazide-reserpine. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - May 6, 1982
The date Chlorothiazide-reserpine was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Chlorothiazide-reserpine. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Chlorothiazide-reserpine is in. Format is RX, OTC, DISCN.

Applicant Full Name - Mylan Pharmaceuticals Inc
The full name of the firm holding legal responsibility for the new application of Chlorothiazide-reserpine.

Chlorothiazide-reserpine